Lexeo Therapeutics (LXEO) Interest Expenses (2022 - 2026)

Lexeo Therapeutics has reported Interest Expenses for 5 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Interest Expenses rose 417.82% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 886.32% YoY) and the FY2025 annual result came in at $118.9 million, up 1790.26% from the prior year.
• Interest Expenses grew to $2.8 million in Q1 2026 per LXEO's latest filing, from $2.1 million in the prior quarter.
• Over five years, Interest Expenses peaked at $18.2 million in Q1 2024 and troughed at -$1.4 million in Q4 2024.
• A 5-year average of $4.9 million and a median of $2.1 million in 2025 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 3354.04% in 2024, down 2982.0% in 2024.
• Over 5 years, Interest Expenses stood at -$193000.0 in 2022, then jumped by 125.91% to $50000.0 in 2023, then tumbled by 2982.0% to -$1.4 million in 2024, then soared by 244.14% to $2.1 million in 2025, then surged by 32.88% to $2.8 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $2.8 million, $2.1 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.